morphine sulfate


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.

mor·phine sul·fate (MS),

morphine used for formulation of tablets as well as solutions for parenteral, epidural, or intrathecal injection to relieve pain.

morphine sulfate

an opioid analgesic.
indications It is prescribed for relief of moderate to severe pain, including that from myocardial infarction and dyspnea caused by left heart failure, and as a preanesthetic.
contraindications Drug dependence or known hypersensitivity to this drug prohibits its use.
adverse effects Among the more serious adverse effects are increased intracranial pressure, cardiovascular disturbances, respiratory depression, and drug dependence. Nausea, vomiting, constipation, and xerostomia are common.

mor·phine sul·fate

(mōr'fēn sŭl'fāt)
Agent used for formulation of tablets as well as solutions for parenteral, epidural, or intrathecal injection to relieve pain.

mor·phine sul·fate

(MS) (mōr'fēn sŭl'fāt)
Morphine used for parenteral, epidural, or intrathecal injection to relieve pain.

morphine sulfate,

n brand names: Duramorph PF, MS Contin, Roxanol;
drug class: narcotic analgesic (Controlled Substance Schedule II);
action: depresses pain impulse transmission at the central nervous system by interacting with opioid receptors;
use: severe pain.
References in periodicals archive ?
A prospective double blind placebo controlled clinical trial was per- formed in 2010 by Ziegler et al6 evaluating the analgesic effects of morphine in patients with TMJD concluded that 10mg morphine sulfate intra-articular injection give the best and long lasting analgesic effect.
No adducted nucleotides could be detected on chromatograms prepared from cells treated either saline or mitomycin C followed by incubated with either saline of morphine sulfate for an additional 2 h.
Respiratory depression is the primary risk of morphine sulfate.
In response to the outcry, the FDA sent follow-up letters on April 9 to six companies that offer the concentrated morphine sulfate elixir, saying they could continue to market the drug formulation.
Pharmaceutical products company Lannett Company (NYSE:LCI) reported on Monday the receipt of approval from the US Food and Drug Administration (FDA) of its Supplemental New Drug Application (sNDA) for Morphine Sulfate Oral Solution CII with added color and flavour in 20 mg/ml for acute and chronic pain.
In April, 2009, the FDA announced that manufacturers could keep morphine sulfate oral solution on the market, but only until the product was approved, or an equivalent, approved therapy was available.
Oral morphine sulfate appears to be a promising treatment for obsessive-compulsive disorder that is resistant to conventional therapies, Dr.
Food and Drug Administration (FDA) has approved the company's 505(b)(2) New Drug Application (NDA) for Morphine Sulfate Oral Solution on June 23, 2011.
The five currently marketed products include morphine sulfate extended release capsules, the generic version of Kadian; fentanyl transdermal system CII, the generic equivalent of Duragesic; nifedipine extended release tablets, the generic version of Adalat CC; diltiazem hydrochloride extended release capsules, the generic equivalent of Cardizem CD; and metoclopramide hydrochloride tablets, the generic version of Reglan.
M2 PHARMA-August 9, 2012-Perrigo Company unveils FDA approved Morphine Sulfate 100ml/5% Oral Solution for moderate to severe acute and chronic pain(C)2012 M2 COMMUNICATIONS
has received approval of its ANDA for morphine sulfate extended-release tablets, 15 mg, 30 mg, 60 mg, 100 mg and 200 mg, the generic version of Purdue Pharma's MS Contin, an opioid analgesic for moderate to severe pain management.
Food and Drug Administration (FDA) has issued a revised Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2011 for the company's 505(b)(2) New Drug Application for Morphine Sulfate Oral Solution.